Skyland Bio-Technology

Skyland Bio-Technology is a clinical-stage biotechnology company headquartered in China, dedicated to the development of next-generation gene therapies using adeno-associated virus (AAV) vectors. Founded by industry veterans with extensive experience in viral vector engineering, the company focuses on addressing rare genetic diseases with high unmet medical needs, particularly in hematology and metabolic disorders. Its lead program, SKL-001, is an AAV-based gene therapy for Hemophilia B that has progressed into clinical trials. Skyland Bio-Technology operates a fully integrated platform that encompasses vector design, process development, and large-scale GMP manufacturing. The company aims to provide curative, one-time treatments for patients globally through its innovative genetic medicine approach.